Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | HBB | P68871 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 4/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4242154 | 0.86 | LMNA (0.36) | ALDH1A1LMNA | |
| SCHEMBL10106473 | 0.79 | HPGD (0.38) | ALDH1A1LMNATP53MAPK1SMN1; SMN2 | |
| SCHEMBL17620947 | 0.77 | ATR (0.36) | CA2 | |
| SCHEMBL17771171 | 0.77 | MEN1 (0.39) | ALDH1A1LMNA | |
| SCHEMBL8906669 | 0.77 | CA2 (0.44) | RELACA2 | |
| SCHEMBL7771896 | 0.77 | MEN1 (0.32) | — | |
| SCHEMBL26144799 | 0.76 | — | — | |
| SCHEMBL17520384 | 0.76 | CA2 (0.47) | RELACA2 | |
| SCHEMBL21503860 | 0.76 | MEN1 (0.38) | ALDH1A1LMNA | |
| SCHEMBL19776090 | 0.76 | CA2 (0.47) | RELACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591301-B2 | Indoleamine-2,3-dioxygenase inhibitor, preparation method therefor and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2023-02-28 | — | — | US | disclosed |
| US-20210047281-A1 | INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | HINOVA PHARMACEUTICALS INC. (CN) | 2021-02-18 | — | — | US | disclosed |
| WO-2019149255-A1 | INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 成都海创药业有限公司 | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591301-B2 | Indoleamine-2,3-dioxygenase inhibitor, preparation method therefor and use thereof | IDO1, IDO2, TPH1 | APP 689/4885GMNN 3461/4885ALDH1A1 741/4885 |
| US-20210047281-A1 | INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | IDO1, IDO2, TPH1 | APP 689/4885GMNN 3461/4885ALDH1A1 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.